Monness, Crespi, Hardt Starts ARIAD Pharma (ARIA) at Buy, $22 Price Target
Tweet
Share
E-mailGet Alerts ARIA Hot Sheet
Price: $25.78 -0.96%
Rating Summary:
10 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
10 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Monness, Crespi, Hardt initiated coverage on shares of ARIAD Pharmaceuticals (NASDAQ: ARIA) with a Buy rating and a $22.00 price target.
With the stock up 1.6 percent to $12.08 Monday afternoon, the firm's new price target represents potential upside of about 82 percent.
For more ratings news on ARIAD Pharmaceuticals click here and for the rating history of ARIAD Pharmaceuticals click here.
With the stock up 1.6 percent to $12.08 Monday afternoon, the firm's new price target represents potential upside of about 82 percent.
For more ratings news on ARIAD Pharmaceuticals click here and for the rating history of ARIAD Pharmaceuticals click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exchange Traded Concepts and ARIAM Global launch ARIA an Actively Managed ETF Led by a Portfolio Manager with a Ph.D. in AI and Computer Science
- Leerink Starts Freenome Inc. (FRNM) at Outperform
- Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
